US 11,655,294 B2
Methods and compositions for the treatment of celiac disease, non-celiac gluten sensitivity, and refractory celiac disease
Francisco Leon, Bethesda, MD (US); and Wayne H. Tsuji, Seattle, WA (US)
Assigned to AMGEN INC., Thousand Oaks, CA (US); and CELIMMUNE LLC, Thousand Oaks, CA (US)
Filed by Celimmune LLC, Thousand Oaks, CA (US); and AMGEN INC., Thousand Oaks, CA (US)
Filed on Jan. 14, 2020, as Appl. No. 16/741,897.
Application 16/741,897 is a continuation of application No. 15/622,990, filed on Jun. 14, 2017, abandoned.
Claims priority of provisional application 62/350,660, filed on Jun. 15, 2016.
Prior Publication US 2020/0385451 A1, Dec. 10, 2020
Int. Cl. C07K 16/24 (2006.01); A61K 39/395 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/243 (2013.01) [A61K 39/395 (2013.01); C07K 16/244 (2013.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); C07K 2317/21 (2013.01); C07K 2317/56 (2013.01)] 7 Claims
 
1. A method of treating celiac disease or non-celiac gluten sensitivity in a subject in need thereof, comprising administering about 300 mg of an anti-IL-15 antibody or antigen-binding fragment thereof to the subject about once every 2 weeks, wherein said anti-IL-15 antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising complementarity determining regions (CDRs) set forth in SEQ ID NOs: 5-7, and a light chain variable region comprising CDRs set forth in SEQ ID NOs: 8-10.